THE GLOBAL LIQUID BIOPSY MARKET IS EXPECTED TO REACH USD 12.16 BILLION BY 2028 FROM USD 3.48 BILLION IN 2022, GROWING AT A CAGR OF 23.19% DURING THE FORECAST PERIOD.

The Liquid Biopsy Market Size, Share, & Trends Analysis Report By

  • Product: Kits & Reagents and Instruments & Platforms
  • Sample Type: Blood and Others
  • Application: Cancer and Non-cancer
  • Biomarker Type: Cell-free DNA (cfDNA) and circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), and Extracellular Vesicles (EVs)
  • Technology: Next-generation Sequencing (NGS) and Polymerase Chain Reaction (PCR)
  • End-user: Hospitals, Diagnostic Laboratories, and Others
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

377 Pages

icon-table

235 Tables

icon-chart

150 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

26 Companies

icon-market

7 Market Segment

LIQUID BIOPSY MARKET REPORT SCOPE

Report Attribute Details
Market Size (2028) USD 12.16 Billion
Market Size (2022) USD 3.48 Billion
CAGR (2022-2028) 23.19%
BASE YEAR 2022
FORECAST YEAR 2023-2028
SEGMENTS BY Product, Sample Type, Application, Biomarker Type, Technology, End-user, and Geography
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, and Middle East & Africa
KEY PLAYERS Agilent Technologies, F. Hoffmann-La Roche, Guardant Health, Illumina, QIAGEN, and Thermo Fisher Scientific

MARKET OUTLOOK

The global liquid biopsy market was valued at USD 3.48 billion in 2022 and is expected to reach USD 12.16 billion by 2028, growing at a CAGR of 23.19%. The primary application of liquid biopsy lies in the field of oncology. It enables early cancer detection, facilitates personalized treatment decisions, monitors treatment response, detects minimal residual disease, and aids in identifying emerging mutations and therapeutic targets. The liquid biopsy market is also promising for diagnosing and monitoring other diseases, including infectious diseases, cardiovascular disorders, and prenatal screening. Several technologies are employed in liquid biopsy, including next-generation sequencing (NGS), PCR, mass spectrometry, and microfluidics. These advanced techniques enable the detection and characterization of rare tumor-specific genetic alterations and other biomarkers in a minimally invasive manner.

Liquid biopsy has emerged as a ground-breaking and non-invasive medical diagnostic approach, offering a revolutionary method for detecting and monitoring diseases, particularly cancer. Unlike traditional tissue biopsies, which require invasive procedures, liquid biopsy involves the analysis of biomarkers present in various biofluids, such as blood, urine, or cerebrospinal fluid. This innovative technique has garnered immense attention and is transforming the landscape of precision medicine and oncology. The liquid biopsy market can revolutionize how diseases, especially cancer, are diagnosed, monitored, and treated. It offers several advantages over conventional tissue biopsies, including its non-invasive nature, its ability to provide real-time and dynamic information about the disease, and the possibility of capturing tumor heterogeneity. By detecting and analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers, liquid biopsy provides insights into genetic alterations, tumor mutations, treatment response, minimal residual disease, and the development of resistance.

While liquid biopsy has garnered significant attention and demonstrated its potential, challenges remain to be addressed. Technical limitations, such as the sensitivity and specificity of assays, standardization of protocols, and data interpretation, are areas of ongoing research. Regulatory considerations, reimbursement policies, and integration into clinical practice also challenge the liquid biopsy market. Despite these challenges in the liquid biopsy market, the rapid advancements in technology, increasing clinical evidence, and growing investments in research and development are propelling the liquid biopsy field forward. As the understanding of the molecular mechanisms of diseases deepens and technology continues to improve, the liquid biopsy market holds immense promise for revolutionizing diagnostics, patient management, and therapeutic decision-making across various medical specialties.

Liquid Biopsy Market Report by Arizton

MARKET TRENDS & DRIVERS

Increasing Role of Liquid Biopsy as a Companion Diagnostics
As liquid biopsy technologies continue to advance, their role as companion diagnostics is expanding rapidly. The non-invasive nature, ability to capture tumor heterogeneity and dynamics, early detection of MRD, real-time treatment response assessment, targeted therapy selection, and biomarker discovery make liquid biopsy an invaluable tool in guiding personalized treatment strategies. The integration of liquid biopsy as a companion diagnostic is transforming the field of precision medicine, leading to more effective and tailored therapeutic approaches for patients.

New Product Launches
The liquid biopsy market has witnessed several notable product launches in recent years. Companies like Guardant Health, Roche, and Illumina have introduced innovative solutions to enhance liquid biopsy capabilities. These include new liquid biopsy assays with expanded gene panels, improved sensitivity, and increased accuracy. Advanced platforms and technologies, such as digital PCR and next-generation sequencing (NGS), have also been introduced to enable more comprehensive and precise analysis of circulating biomarkers. Bioinformatics tools and software have also been developed to facilitate data analysis and interpretation, enhancing the clinical utility of liquid biopsy.

Higher Patient Preference for Non-invasive Diagnosis and Monitoring
The preference for non-invasive diagnosis and monitoring methods has become a significant driver for the liquid biopsy industry. Patients and healthcare providers increasingly recognize the advantages of liquid biopsy over invasive tissue biopsies, such as reduced procedural risks, minimal discomfort, and the ability to obtain multiple samples over time. Liquid biopsy's non-invasive nature also allows for easier accessibility, especially in cases where obtaining tissue biopsies may be challenging or impractical. The growing demand for non-invasive diagnostic approaches aligns with the convenience, safety, and potential for real-time monitoring offered by liquid biopsy, contributing to its expanding adoption and market growth.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT
The kits & reagents product segment dominated the global liquid biopsy market and is projected to witness the fastest growth rate of over 23% during the forecast period. Liquid biopsy kits and reagents are tools used to detect and diagnose cancer. Liquid biopsy kits and reagents are designed to detect and analyze specific biomarkers in the blood, urine, saliva, or other bodily fluids. Different reagents may be used to identify and measure the biomarkers depending on the type of liquid sample used. Overall, liquid biopsy kits and reagents have revolutionized the field of cancer detection and diagnosis. With these tools, clinicians can now detect and diagnose cancer more accurately, quickly, and cost-effectively than ever before.

INSIGHTS BY SAMPLE TYPE
The global liquid biopsy market by sample type segments as blood and others. The blood segment held the largest global market share. The development of liquid biopsy has revolutionized medical diagnostics and changed how we approach disease treatment. Liquid biopsy is a type of biopsy procedure involving the extraction of genetic material from a patient’s blood or other bodily fluid for disease diagnosis and prognosis. One of the most common and widely used liquid biopsy methods is the analysis of blood samples.

INSIGHTS BY APPLICATION
The global liquid biopsy market by application segments by cancer and non-cancer.The cancer segment accounted for the largest global liquid biopsy market share. Cancer is a major health concern, and its early detection is critical for successful treatment. Unfortunately, traditional invasive biopsies are often painful, expensive, and not always suitable for cancer detection. As a result, liquid biopsy has emerged as an attractive alternative, offering the potential to detect cancer earlier and with less risk. A liquid biopsy is a minimally invasive procedure that analyzes molecules in body fluids such as blood or urine to detect cancer. By analyzing cancer-specific molecules, such as circulating tumor DNA, commonly known as ctDNA, or circulating tumor cells, liquid biopsies can accurately diagnose cancer before the tumor becomes visible.

INSIGHTS BY BIOMARKER TYPE
The cfDNA & ctDNA biomarker type segment dominated the global liquid biopsy market, accounting for over 41% in 2022. Cell-free DNA (cfDNA) is a rapidly developing technology in liquid biopsy that has opened up a new field of cancer diagnosis and patient management. It involves DNA extraction from a sample of circulating blood, which can then be analyzed for the presence of genetic mutations. These mutations are associated with cancer development and can provide a detailed picture of a patient’s disease.

INSIGHTS BY TECHNOLOGY
The next-generation sequencing (NGS) technology segment dominated the global liquid biopsy market in 2022. Liquid biopsy is a revolutionary technique that has transformed the field of cancer diagnosis and treatment. In particular, liquid biopsy has greatly advanced the study of cancer genomics using NGS. NGS is a powerful and cost-effective technology that enables the rapid sequencing of large amounts of genetic material. NGS sequences the sample's genetic material and identifies any cancer-related mutations. Through this process, researchers can detect cancer at earlier stages and determine the type and aggressiveness of the cancer. The data generated from NGS can be used to develop targeted therapies and improve patient outcomes.

INSIGHTS BY END-USER
The hospital end-user segment accounted for the largest global liquid biopsy market share. As medical technology advances, liquid biopsy in hospitals is becoming more commonplace. Liquid biopsy is a relatively new technology that utilizes a patient’s blood, urine, or other body fluids to detect cancer cells or biomarkers. This method offers an alternative to traditional tissue biopsies, which are invasive, painful, and expensive. By detecting cancer cells or markers from a simple blood or urine sample, liquid biopsy can provide non-invasive, cost-effective, and timely diagnostic information. The use of liquid biopsy in hospitals is increasing due to its versatility and convenience. It can detect various cancers, including breast, colorectal, lung, prostate, and ovarian. It can also detect cancer at earlier stages, providing earlier diagnosis and treatment. Using liquid biopsy for cancer detection is also beneficial because it can monitor real-time response to treatment, such as chemotherapy or immunotherapy.

GEOGRAPHICAL ANALYSIS

North America dominated the global liquid biopsy market share, accounting for over 48% in 2022. The increasing demand for liquid biopsy technology in North America comes in the face of growing cancer rates across the U.S. and Canada, as well as an increased awareness of the early diagnostic benefits of this technology. Liquid biopsies can provide detailed information on the presence of the disease, its type, and its progression in the body much earlier than traditional methods and procedures.

The growth of the global liquid biopsy market is among Europe's most disruptive developments in cancer treatments. Since it involves a non-invasive testing method, liquid biopsy can be extremely beneficial for elderly or fragile patients, as it reduces the risk of complications arising from sampling tissue from the body. This makes it one of the best and most efficient options for early detection of cancerous cells in these patients, and as a result, many European governments have started to invest widely in its research. In addition, due to the enhanced accuracy of liquid biopsy testing compared to mechanical biopsies, its use is now more widely accepted among medical professionals in many European countries.

COMPETITIVE LANDSCAPE

Competing in the global liquid biopsy market demands robust clinical validation and regulatory approvals. Companies that successfully navigate regulatory pathways, obtain approvals from health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and provide solid clinical evidence gain a competitive advantage. Validated assays with regulatory endorsements instill confidence in healthcare professionals and contribute to industry penetration. Continuous advancements in sequencing technologies, digital PCR, and other analytical platforms have improved the sensitivity and specificity of liquid biopsy tests. These advancements enhance the ability to detect rare mutations and monitor tumor heterogeneity.

The global liquid biopsy market is highly competitive, with key players focused on developing innovative solutions and expanding their market presence. Advancements in technology, increasing clinical adoption, and strategic collaborations are shaping the landscape of this dynamic industry. Key players in the global liquid biopsy market are forming strategic partnerships and collaborations with pharmaceutical companies, research institutions, and diagnostic laboratories. Further, these partnerships aim to leverage complementary expertise, expand market reach, and accelerate the development of novel liquid biopsy assays.

Frequently Asked Questions

How big is the liquid biopsy market?

The global liquid biopsy market was valued at USD 3.48 billion in 2022 and is expected to reach USD 12.16 billion by 2028.

What is the growth rate of the global liquid biopsy market?

The global liquid biopsy market is expected to grow at a CAGR of 23.19% from 2022 to 2028.

Which region dominates the global liquid biopsy market share?

North America held the largest global liquid biopsy market share, accounting for over 48% of global revenue in 2022.

What are the significant trends in the liquid biopsy industry?

The increasing role of liquid biopsy as a companion diagnostics, government initiatives & funding for liquid biopsy, emerging usage of liquid biopsy in non-cancer applications, and new product launches are significant trends in the liquid biopsy industry.

Who are the key players in the global liquid biopsy market?

Agilent Technologies, F. Hoffmann-La Roche, Guardant Health, Illumina, QIAGEN, and Thermo Fisher Scientific are the key players in the global liquid biopsy market.

Download Free Sample

The global liquid biopsy market size is expected to grow at a CAGR of approximately 23.19% from 2022 to 2028.

The following factors are likely to contribute to the growth of the liquid biopsy market during the forecast period:

  • Rising Global Cancer Prevalence
  • Higher Patient Preference for Non-invasive Diagnosis and Monitoring
  • Technological Advances in Clinical Applications of Liquid Biopsies
  • Transformation in Precision Cancer Care

Base Year: 2022

Forecast Year: 2023-2028

The report considers the present scenario of the global liquid biopsy market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

Key Company Profiles

  • Agilent Technologies
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • F. Hoffmann-La Roche
  • Guardant Health
  • Illumina
  • QIAGEN
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Agena Bioscience
    • Business Overview
    • Product Offerings
  • ANGLE
  • Biocept
  • Biodesix
  • Biolidics
  • Bio-Rad Laboratories
  • BIOVIEW
  • Caris Life Sciences
  • Epigenomics
  • Freenome Holdings
  • Invitae Corporation
  • Laboratory Corporation of America
  • Lucence Health
  • LungLife AI
  • mdxhealth
  • Menarini Silicon Biosystems
  • Natera
  • NeoGenomics Laboratories
  • Sysmex Corporation
  • TEMPUS

Segmentation by Product

  • Kits & Reagents
  • Instruments & Platforms

Segmentation by Sample Type

  • Blood
  • Others

Segmentation by Application

  • Cancer
  • Non-cancer

Segmentation by Biomarker Type

  • Cell-free DNA (cfDNA) & Circulating Tumor DNA (ctDNA)
  • Circulating Tumor Cells (CTCs)
  • Extracellular Vesicles (EVs)

Segmentation by Technology

  • Next-generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)

Segmentation by End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others

Segmentation by Geography

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS

4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT
4.3.2 MARKET SEGMENTATION BY SAMPLE TYPE
4.3.3 MARKET SEGMENTATION BY APPLICATION
4.3.4 MARKET SEGMENTATION BY BIOMARKER TYPE
4.3.5 MARKET SEGMENTATION BY TECHNOLOGY
4.3.6 MARKET SEGMENTATION BY END-USER
4.3.7 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS
6.1 OVERVIEW
6.1.1 GEOGRAPHY INSIGHTS
6.1.2 PRODUCT INSIGHTS
6.1.3 SAMPLE TYPE
6.1.4 APPLICATION INSIGHTS
6.1.5 BIOMARKER TYPE
6.1.6 TECHNOLOGY INSIGHTS
6.1.7 END-USER INSIGHTS

7 MARKET AT A GLANCE
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 ROLE OF LIQUID BIOPSY AS A COMPANION DIAGNOSTICS
9.2 GOVERNMENT INITIATIVES & FUNDING FOR LIQUID BIOPSY
9.3 USE OF LIQUID BIOPSY IN NON-CANCER APPLICATIONS
9.4 NEW PRODUCT LAUNCHES

10 MARKET GROWTH ENABLERS
10.1 HIGH GLOBAL CANCER PREVALENCE
10.2 PATIENT PREFERENCE FOR NON-INVASIVE DIAGNOSIS & MONITORING
10.3 TECHNOLOGICAL ADVANCES IN CLINICAL APPLICATIONS OF LIQUID BIOPSY
10.4 TRANSFORMATION OF PRECISION CANCER CARE

11 MARKET RESTRAINTS
11.1 HIGH COST OF LIQUID BIOPSY COMPARED WITH TRADITIONAL BIOPSY
11.2 ACCEPTANCE & AWARENESS OF LIQUID BIOPSIES IN LMICS
11.3 LACK OF SKILLED WORKFORCE

12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET BY GEOGRAPHY
12.3.2 MARKET BY PRODUCT
12.3.3 MARKET BY SAMPLE TYPE
12.3.4 MARKET BY APPLICATION
12.3.5 MARKET BY BIOMARKER TYPE
12.3.6 MARKET BY TECHNOLOGY
12.3.7 MARKET BY END-USER
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY

13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 KITS & REAGENTS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 KITS & REAGENTS SEGMENT BY GEOGRAPHY
13.4 INSTRUMENTS & PLATFORMS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 INSTRUMENTS & PLATFORMS SEGMENT BY GEOGRAPHY

14 SAMPLE TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 BLOOD
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 BLOOD SEGMENT BY GEOGRAPHY
14.4 OTHER SAMPLES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 OTHER SAMPLES SEGMENT BY GEOGRAPHY

15 APPLICATION
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 CANCER
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 CANCER SEGMENT BY GEOGRAPHY
15.4 NON-CANCER
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 NON-CANCER SEGMENT BY GEOGRAPHY

16 BIOMARKER TYPE
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 CFDNA & CTDNA
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 CFDNA & CTDNA SEGMENT BY GEOGRAPHY
16.4 CTCS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 CTCS SEGMENT BY GEOGRAPHY
16.5 EXTRACELLULAR VESICLES
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 EXTRACELLULAR VESICLES SEGMENT BY GEOGRAPHY

17 TECHNOLOGY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 NGS
17.3.1 MARKET OVERVIEW
17.3.2 MARKET SIZE & FORECAST
17.3.3 NGS SEGMENT BY GEOGRAPHY
17.4 PCR
17.4.1 MARKET OVERVIEW
17.4.2 MARKET SIZE & FORECAST
17.4.3 PCR SEGMENT BY GEOGRAPHY

18 END-USER
18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 MARKET OVERVIEW
18.3 HOSPITALS
18.3.1 MARKET OVERVIEW
18.3.2 MARKET SIZE & FORECAST
18.3.3 HOSPITALS SEGMENT BY GEOGRAPHY
18.4 DIAGNOSTIC LABORATORIES
18.4.1 MARKET OVERVIEW
18.4.2 MARKET SIZE & FORECAST
18.4.3 DIAGNOSTIC LABORATORIES SEGMENT BY GEOGRAPHY
18.5 OTHER END-USERS
18.5.1 MARKET OVERVIEW
18.5.2 MARKET SIZE & FORECAST
18.5.3 OTHERS SEGMENT BY GEOGRAPHY

19 GEOGRAPHY
19.1 MARKET SNAPSHOT & GROWTH ENGINE
19.2 GEOGRAPHIC OVERVIEW

20 NORTH AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 NORTH AMERICA MARKET BY PRODUCT
20.2.2 NORTH AMERICA MARKET BY SAMPLE TYPE
20.2.3 NORTH AMERICA MARKET BY APPLICATION
20.2.4 NORTH AMERICA MARKET BY BIOMARKER TYPE
20.2.5 NORTH AMERICA MARKET BY TECHNOLOGY
20.2.6 NORTH AMERICA MARKET BY END-USER
20.3 KEY COUNTRIES
20.3.1 US: MARKET SIZE & FORECAST
20.3.2 CANADA: MARKET SIZE & FORECAST

21 EUROPE
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 EUROPE MARKET BY PRODUCT
21.2.2 EUROPE MARKET BY SAMPLE TYPE
21.2.3 EUROPE MARKET BY APPLICATION
21.2.4 EUROPE MARKET BY BIOMARKER TYPE
21.2.5 EUROPE MARKET BY TECHNOLOGY
21.2.6 EUROPE MARKET BY END-USER
21.3 KEY COUNTRIES
21.3.1 GERMANY: MARKET SIZE & FORECAST
21.3.2 FRANCE: MARKET SIZE & FORECAST
21.3.3 UK: MARKET SIZE & FORECAST
21.3.4 ITALY: MARKET SIZE & FORECAST
21.3.5 SPAIN: MARKET SIZE & FORECAST

22 APAC
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 APAC MARKET BY PRODUCT
22.2.2 APAC MARKET BY SAMPLE TYPE
22.2.3 APAC MARKET BY APPLICATION
22.2.4 APAC MARKET BY BIOMARKER TYPE
22.2.5 APAC MARKET BY TECHNOLOGY
22.2.6 APAC MARKET BY END-USER
22.3 KEY COUNTRIES
22.3.1 CHINA: MARKET SIZE & FORECAST
22.3.2 JAPAN: MARKET SIZE & FORECAST
22.3.3 INDIA: MARKET SIZE & FORECAST
22.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
22.3.5 AUSTRALIA: MARKET SIZE & FORECAST

23 LATIN AMERICA
23.1 MARKET OVERVIEW
23.2 MARKET SIZE & FORECAST
23.2.1 LATIN AMERICA MARKET BY PRODUCT
23.2.2 LATIN AMERICA MARKET BY SAMPLE TYPE
23.2.3 LATIN AMERICA MARKET BY APPLICATION
23.2.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
23.2.5 LATIN AMERICA MARKET BY TECHNOLOGY
23.2.6 LATIN AMERICA MARKET BY END-USER
23.3 KEY COUNTRIES
23.3.1 BRAZIL: MARKET SIZE & FORECAST
23.3.2 MEXICO: MARKET SIZE & FORECAST
23.3.3 ARGENTINA: MARKET SIZE & FORECAST

24 MIDDLE EAST & AFRICA
24.1 MARKET OVERVIEW
24.2 MARKET SIZE & FORECAST
24.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT
24.2.2 MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE
24.2.3 MIDDLE EAST & AFRICA MARKET BY APPLICATION
24.2.4 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
24.2.5 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
24.2.6 MIDDLE EAST & AFRICA MARKET BY END-USER
24.3 KEY COUNTRIES
24.3.1 TURKEY: MARKET SIZE & FORECAST
24.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
24.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST

25 COMPETITIVE LANDSCAPE
25.1 COMPETITION OVERVIEW
25.2 MARKET SHARE ANALYSIS
25.2.1 AGILENT TECHNOLOGIES
25.2.2 F. HOFFMANN-LA ROCHE
25.2.3 GUARDANT HEALTH
25.2.4 ILLUMINA
25.2.5 QIAGEN
25.2.6 THERMO FISHER SCIENTIFIC

26 KEY COMPANY PROFILES
26.1 AGILENT TECHNOLOGIES
26.1.1 BUSINESS OVERVIEW
26.1.2 PRODUCT OFFERINGS
26.1.3 KEY STRATEGIES
26.1.4 KEY STRENGTHS
26.1.5 KEY OPPORTUNITIES
26.2 F. HOFFMANN-LA ROCHE
26.2.1 BUSINESS OVERVIEW
26.2.2 PRODUCT OFFERINGS
26.2.3 KEY STRATEGIES
26.2.4 KEY STRENGTHS
26.2.5 KEY OPPORTUNITIES
26.3 GUARDANT HEALTH
26.3.1 BUSINESS OVERVIEW
26.3.2 PRODUCT OFFERINGS
26.3.3 KEY STRATEGIES
26.3.4 KEY STRENGTHS
26.3.5 KEY OPPORTUNITIES
26.4 ILLUMINA
26.4.1 BUSINESS OVERVIEW
26.4.2 PRODUCT OFFERINGS
26.4.3 KEY STRATEGIES
26.4.4 KEY STRENGTHS
26.4.5 KEY OPPORTUNITIES
26.5 QIAGEN
26.5.1 BUSINESS OVERVIEW
26.5.2 PRODUCT OFFERINGS
26.5.3 KEY STRATEGIES
26.5.4 KEY STRENGTHS
26.5.5 KEY OPPORTUNITIES
26.6 THERMO FISHER SCIENTIFIC
26.6.1 BUSINESS OVERVIEW
26.6.2 PRODUCT OFFERINGS
26.6.3 KEY STRATEGIES
26.6.4 KEY STRENGTHS
26.6.5 KEY OPPORTUNITIES

27 OTHER PROMINENT VENDORS
27.1 AGENA BIOSCIENCE
27.1.1 BUSINESS OVERVIEW
27.1.2 PRODUCT OFFERINGS
27.2 ANGLE
27.2.1 BUSINESS OVERVIEW
27.2.2 PRODUCT OFFERINGS
27.3 BIOCEPT
27.3.1 BUSINESS OVERVIEW
27.3.2 PRODUCT OFFERINGS
27.4 BIODESIX
27.4.1 BUSINESS OVERVIEW
27.4.2 PRODUCT OFFERINGS
27.5 BIOLIDICS
27.5.1 BUSINESS OVERVIEW
27.5.2 PRODUCT OFFERINGS
27.6 BIO-RAD LABORATORIES
27.6.1 BUSINESS OVERVIEW
27.6.2 PRODUCT OFFERINGS
27.7 BIOVIEW
27.7.1 BUSINESS OVERVIEW
27.7.2 PRODUCT OFFERINGS
27.8 CARIS LIFE SCIENCES
27.8.1 BUSINESS OVERVIEW
27.8.2 PRODUCT OFFERINGS
27.9 EPIGENOMICS
27.9.1 BUSINESS OVERVIEW
27.9.2 PRODUCT OFFERINGS
27.10 FREENOME HOLDINGS
27.10.1 BUSINESS OVERVIEW
27.10.2 PRODUCT OFFERINGS
27.11 INVITAE CORPORATION
27.11.1 BUSINESS OVERVIEW
27.11.2 PRODUCT OFFERINGS
27.12 LABORATORY CORPORATION OF AMERICA
27.12.1 BUSINESS OVERVIEW
27.12.2 PRODUCT OFFERINGS
27.13 LUCENCE HEALTH
27.13.1 BUSINESS OVERVIEW
27.13.2 PRODUCT OFFERINGS
27.14 LUNGLIFE AI
27.14.1 BUSINESS OVERVIEW
27.14.2 PRODUCT OFFERINGS
27.15 MDXHEALTH
27.15.1 BUSINESS OVERVIEW
27.15.2 PRODUCT OFFERINGS
27.16 MENARINI SILICON BIOSYSTEMS
27.16.1 BUSINESS OVERVIEW
27.16.2 PRODUCT OFFERINGS
27.17 NATERA
27.17.1 BUSINESS OVERVIEW
27.17.2 PRODUCT OFFERINGS
27.18 NEOGENOMICS LABORATORIES
27.18.1 BUSINESS OVERVIEW
27.18.2 PRODUCT OFFERINGS
27.19 SYSMEX CORPORATION
27.19.1 BUSINESS OVERVIEW
27.19.2 PRODUCT OFFERINGS
27.20 TEMPUS
27.20.1 BUSINESS OVERVIEW
27.20.2 PRODUCT OFFERINGS

28 REPORT SUMMARY
28.1 KEY TAKEAWAYS
28.2 STRATEGIC RECOMMENDATIONS

29 QUANTITATIVE SUMMARY
29.1 MARKET BY PRODUCT
29.1.1 NORTH AMERICA MARKET BY PRODUCT
29.1.2 EUROPE MARKET BY PRODUCT
29.1.3 APAC MARKET BY PRODUCT
29.1.4 LATIN AMERICA MARKET BY PRODUCT
29.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT
29.2 MARKET BY SAMPLE TYPE
29.2.1 NORTH AMERICA MARKET BY SAMPLE TYPE
29.2.2 EUROPE MARKET BY SAMPLE TYPE
29.2.3 APAC MARKET BY SAMPLE TYPE
29.2.4 LATIN AMERICA MARKET BY SAMPLE TYPE
29.2.5 MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE
29.3 MARKET BY APPLICATION
29.3.1 NORTH AMERICA MARKET BY APPLICATION
29.3.2 EUROPE MARKET BY APPLICATION
29.3.3 APAC MARKET BY APPLICATION
29.3.4 LATIN AMERICA MARKET BY APPLICATION
29.3.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
29.4 MARKET BY BIOMARKER TYPE
29.4.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
29.4.2 EUROPE MARKET BY BIOMARKER TYPE
29.4.3 APAC MARKET BY BIOMARKER TYPE
29.4.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
29.4.5 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
29.5 MARKET BY TECHNOLOGY
29.5.1 NORTH AMERICA MARKET BY TECHNOLOGY
29.5.2 EUROPE MARKET BY TECHNOLOGY
29.5.3 APAC MARKET BY TECHNOLOGY
29.5.4 LATIN AMERICA MARKET BY TECHNOLOGY
29.5.5 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
29.6 MARKET BY END-USER
29.6.1 NORTH AMERICA MARKET BY END-USER
29.6.2 EUROPE MARKET BY END-USER
29.6.3 APAC MARKET BY END-USER
29.6.4 LATIN AMERICA MARKET BY END-USER
29.6.5 MIDDLE EAST & AFRICA MARKET BY END-USER
29.7 MARKET BY GEOGRAPHY
29.7.1 KITS & REAGENTS SEGMENT BY GEOGRAPHY
29.7.2 INSTRUMENTS & PLATFORMS SEGMENT BY GEOGRAPHY
29.7.3 BLOOD SEGMENT BY GEOGRAPHY
29.7.4 OTHER SAMPLES SEGMENT BY GEOGRAPHY
29.7.5 CANCER SEGMENT BY GEOGRAPHY
29.7.6 NON-CANCER SEGMENT BY GEOGRAPHY
29.7.7 CFDNA & CTDNA SEGMENT BY GEOGRAPHY
29.7.8 CTCS SEGMENT BY GEOGRAPHY
29.7.9 EXTRACELLULAR VESICLES SEGMENT BY GEOGRAPHY
29.7.10 NGS SEGMENT BY GEOGRAPHY
29.7.11 PCR SEGMENT BY GEOGRAPHY
29.7.12 HOSPITALS SEGMENT BY GEOGRAPHY
29.7.13 DIAGNOSTIC LABORATORIES SEGMENT BY GEOGRAPHY
29.7.14 OTHER END-USERS SEGMENT BY GEOGRAPHY

30 APPENDIX
30.1 ABBREVIATIONS

EXHIBIT 1 SEGMENTATION OF GLOBAL LIQUID BIOPSY MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 6 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 7 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 8 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 9 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 10 IMPACT OF ROLE OF LIQUID BIOPSY AS A COMPANION DIAGNOSTICS
EXHIBIT 11 IMPACT OF GOVERNMENT INITIATIVES & FUNDING FOR LIQUID BIOPSY
EXHIBIT 12 IMPACT OF USE OF LIQUID BIOPSY IN NON-CANCER APPLICATIONS
EXHIBIT 13 IMPACT OF NEW PRODUCT LAUNCHES
EXHIBIT 14 IMPACT OF HIGH GLOBAL CANCER PREVALENCE
EXHIBIT 15 IMPACT OF PATIENT PREFERENCE FOR NON-INVASIVE DIAGNOSIS & MONITORING
EXHIBIT 16 IMPACT OF TECHNOLOGICAL ADVANCES IN CLINICAL APPLICATIONS OF LIQUID BIOPSY
EXHIBIT 17 IMPACT OF TRANSFORMATION OF PRECISION CANCER CARE
EXHIBIT 18 IMPACT OF HIGH COST OF LIQUID BIOPSY COMPARED WITH TRADITIONAL BIOPSY
EXHIBIT 19 IMPACT OF ACCEPTANCE & AWARENESS OF LIQUID BIOPSIES IN LMICS
EXHIBIT 20 IMPACT OF LACK OF SKILLED WORKFORCE
EXHIBIT 21 GLOBAL LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 22 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 23 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 24 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 25 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 26 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 27 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 28 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 29 FIVE FORCES ANALYSIS 2022
EXHIBIT 30 INCREMENTAL GROWTH BY PRODUCT 2022 & 2028
EXHIBIT 31 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 32 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: ABSOLUTE GROWTH (%)
EXHIBIT 33 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 35 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 36 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 37 INCREMENTAL GROWTH BY SAMPLE TYPE 2022 & 2028
EXHIBIT 38 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 39 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 40 GLOBAL BLOOD LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL BLOOD LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 42 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY APPLICATION 2022 & 2028
EXHIBIT 45 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 46 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: ABSOLUTE GROWTH (%)
EXHIBIT 47 GLOBAL CANCER LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL CANCER LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 49 GLOBAL NON-CANCER LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL NON-CANCER LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 51 INCREMENTAL GROWTH BY BIOMARKER TYPE 2022 & 2028
EXHIBIT 52 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 53 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 54 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 56 GLOBAL CTCS LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL CTCS LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 58 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY TECHNOLOGY 2022 & 2028
EXHIBIT 61 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 62 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: ABSOLUTE GROWTH (%)
EXHIBIT 63 GLOBAL NGS LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL NGS LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 65 GLOBAL PCR LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL PCR LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 67 INCREMENTAL GROWTH BY END-USER 2022 & 2028
EXHIBIT 68 GLOBAL LIQUID BIOPSY MARKET BY END-USER: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 69 GLOBAL LIQUID BIOPSY MARKET BY END-USER: ABSOLUTE GROWTH (%)
EXHIBIT 70 GLOBAL HOSPITALS LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 GLOBAL HOSPITALS LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 72 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 74 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 76 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
EXHIBIT 77 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 78 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 79 NORTH AMERICA LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 80 NORTH AMERICA LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 NORTH AMERICA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 82 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
EXHIBIT 83 US PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 84 US LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 85 CANADA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 86 EUROPE LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 87 EUROPE LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 88 EUROPE LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 89 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
EXHIBIT 90 GERMANY PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 91 GERMANY LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 92 FRANCE PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 93 FRANCE LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 94 UK PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 95 UK LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 96 ITALY PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 97 ITALY LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 98 SPAIN LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 99 APAC LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 100 APAC LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 101 APAC LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 102 INCREMENTAL GROWTH IN APAC 2022 & 2028
EXHIBIT 103 CHINA PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 104 CHINA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 105 JAPAN PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 106 JAPAN LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 107 INDIA PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 108 INDIA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 109 SOUTH KOREA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 110 AUSTRALIA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 111 LATIN AMERICA LIQUID BIOPSY MARKET 2022–2028: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 112 LATIN AMERICA LIQUID BIOPSY MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 113 LATIN AMERICA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 114 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
EXHIBIT 115 BRAZIL PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 116 BRAZIL LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 117 MEXICO PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 118 MEXICO LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 119 ARGENTINA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 120 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 121 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 122 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 123 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
EXHIBIT 124 TURKEY LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 125 SAUDI ARABIA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 126 SOUTH AFRICA LIQUID BIOPSY MARKET 2022–2028 ($ BILLION)
EXHIBIT 127 VENDORS OFFERING LIQUID BIOPSY PRODUCTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 128 VENDORS OFFERING COMMERCIAL LIQUID BIOPSY PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 129 AGILENT TECHNOLOGIES: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 130 AGILENT TECHNOLOGIES: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 131 AGILENT TECHNOLOGIES: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 132 AGILENT TECHNOLOGIES: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 133 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 134 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 135 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 136 GUARDANT HEALTH: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 137 GUARDANT HEALTH: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 138 GUARDANT HEALTH: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 139 ILLUMINA: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 140 ILLUMINA: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 141 ILLUMINA: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 142 ILLUMINA: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 143 QIAGEN: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 144 QIAGEN: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 145 QIAGEN: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 146 QIAGEN: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 147 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 148 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 149 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 150 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2022 ($ BILLION)

LIST OF TABLES

TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2016–2022
TABLE 3 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 4 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 5 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 6 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 7 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 8 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 9 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 10 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 11 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 12 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 13 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 14 GLOBAL BLOOD LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 15 GLOBAL BLOOD LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 16 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 17 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 18 GLOBAL CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 19 GLOBAL CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 20 GLOBAL NON-CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 21 GLOBAL NON-CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 22 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 23 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 24 GLOBAL CTCS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 25 GLOBAL CTCS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 26 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 27 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 28 GLOBAL NGS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 29 GLOBAL NGS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 30 GLOBAL PCR LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 31 GLOBAL PCR LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 32 GLOBAL HOSPITALS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 33 GLOBAL HOSPITALS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 34 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 35 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 36 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 37 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 38 NORTH AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 39 NORTH AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 40 NORTH AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 41 NORTH AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 42 NORTH AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 43 NORTH AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 44 NORTH AMERICAN LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 45 NORTH AMERICAN LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 46 NORTH AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 47 NORTH AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 48 NORTH AMERICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 49 NORTH AMERICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 50 US CANCER STATISTICS (2020)
TABLE 51 EUROPE LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 52 EUROPE LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 53 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 54 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 55 EUROPE LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 56 EUROPE LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 57 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 58 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 59 EUROPE LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 60 EUROPE LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 61 EUROPE LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 62 EUROPE LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 63 GERMANY CANCER STATISTICS (2020)
TABLE 64 FRANCE CANCER STATISTICS (2020)
TABLE 65 UK CANCER STATISTICS (2020)
TABLE 66 ITALY CANCER STATISTICS (2020)
TABLE 67 APAC LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 68 APAC LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 69 APAC LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 70 APAC LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 71 APAC LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 72 APAC LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 73 APAC LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 74 APAC LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 75 APAC LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 76 APAC LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 77 APAC LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 78 APAC LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 79 CHINA CANCER STATISTICS (2020)
TABLE 80 JAPAN CANCER STATISTICS (2020)
TABLE 81 INDIA CANCER STATISTICS (2020)
TABLE 82 LATIN AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 83 LATIN AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 84 LATIN AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 85 LATIN AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 86 LATIN AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 87 LATIN AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 88 LATIN AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 89 LATIN AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 90 LATIN AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 91 LATIN AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 92 LATIN AMERICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 93 LATIN AMERICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 94 BRAZIL CANCER STATISTICS (2020)
TABLE 95 MEXICO CANCER STATISTICS (2020)
TABLE 96 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 97 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 98 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 99 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 100 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 101 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 102 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 103 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 104 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 105 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 106 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 107 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 108 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 109 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 110 GUARDANT HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 111 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 112 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 113 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 114 AGENA BIOSCIENCE: MAJOR PRODUCT OFFERINGS
TABLE 115 ANGLE: MAJOR PRODUCT OFFERINGS
TABLE 116 BIOCEPT: MAJOR PRODUCT OFFERINGS
TABLE 117 BIODESIX: MAJOR PRODUCT OFFERINGS
TABLE 118 BIOLIDICS: MAJOR PRODUCT OFFERINGS
TABLE 119 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 120 BIOVIEW: MAJOR PRODUCT OFFERINGS
TABLE 121 CARIS LIFE SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 122 EPIGENOMICS: MAJOR PRODUCT OFFERINGS
TABLE 123 FREENOME HOLDINGS: MAJOR PRODUCT OFFERINGS
TABLE 124 INVITAE CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 125 LABORATORY CORPORATION OF AMERICA: MAJOR PRODUCT OFFERINGS
TABLE 126 LUCENCE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 127 LUNGLIFE AI: MAJOR PRODUCT OFFERINGS
TABLE 128 MDXHEALTH: MAJOR PRODUCT OFFERINGS
TABLE 129 MENARINI SILICON BIOSYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 130 NATERA: MAJOR PRODUCT OFFERINGS
TABLE 131 NEOGENOMICS LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 132 SYSMEX CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 133 TEMPUS: MAJOR PRODUCT OFFERINGS
TABLE 134 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 135 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 136 NORTH AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 137 NORTH AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 138 EUROPE LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 139 EUROPE LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 140 APAC LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 141 APAC LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 142 LATIN AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 143 LATIN AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 144 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 145 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2022–2028 (%)
TABLE 146 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 147 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 148 NORTH AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 149 NORTH AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 150 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 151 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 152 APAC LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 153 APAC LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 154 LATIN AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 155 LATIN AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 156 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 ($ BILLION)
TABLE 157 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE 2022–2028 (%)
TABLE 158 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 159 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 160 NORTH AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 161 NORTH AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 162 EUROPE LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 163 EUROPE LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 164 APAC LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 165 APAC LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 166 LATIN AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 167 LATIN AMERICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 168 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 ($ BILLION)
TABLE 169 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY APPLICATION 2022–2028 (%)
TABLE 170 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 171 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 172 NORTH AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 173 NORTH AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 174 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 175 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 176 APAC LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 177 APAC LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 178 LATIN AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 179 LATIN AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 180 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 ($ BILLION)
TABLE 181 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2022–2028 (%)
TABLE 182 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 183 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 184 NORTH AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 185 NORTH AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 186 EUROPE LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 187 EUROPE LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 188 APAC LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 189 APAC LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 190 LATIN AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 191 LATIN AMERICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 192 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 ($ BILLION)
TABLE 193 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY TECHNOLOGY 2022–2028 (%)
TABLE 194 GLOBAL LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 195 GLOBAL LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 196 NORTH AMERICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 197 NORTH AMERICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 198 EUROPE LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 199 EUROPE LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 200 APAC LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 201 APAC LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 202 LATIN AMERICAN LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 203 LATIN AMERICAN LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 204 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 ($ BILLION)
TABLE 205 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY END-USER 2022–2028 (%)
TABLE 206 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 207 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 208 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 209 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 210 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 211 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 212 GLOBAL BLOOD LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 213 GLOBAL BLOOD LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 214 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 215 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 216 GLOBAL CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 217 GLOBAL CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 218 GLOBAL NON-CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 219 GLOBAL NON-CANCER LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 220 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 221 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 222 GLOBAL CTCS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 223 GLOBAL CTCS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 224 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 225 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 226 GLOBAL NGS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 227 GLOBAL NGS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 228 GLOBAL PCR LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 229 GLOBAL PCR LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 230 GLOBAL HOSPITALS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 231 GLOBAL HOSPITALS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 232 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 233 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 234 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 235 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET BY GEOGRAPHY 2022–2028 (%)

Select a license type that suits your business needs

single-user Single User Licence
$4200.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date